Myriad Genetics Q4 2025 revenue $209.8M, net loss $7.9M; reiterates 2026 guidance

MYRIAD GENETICS INC

2025-FY EPS reported -$3.95 revenue$824,500,000

GAAP net loss $7.9M ($0.08 loss per share); adjusted EPS $0.04.
Revenue $209.8M roughly flat YoY; hereditary cancer testing volume +9%, GeneSight +9%, prenatal -6%.
Full-year 2025 revenue $824.5M down 2%; reiterates 2026 revenue guidance $860-880M.
Adjusted EBITDA $14.3M in Q4; company expects 2026 adjusted EBITDA $37-49M.
Plans to launch Precise MRD in March 2026, AI-enabled Prolaris in Q2 2026, FirstGene in H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.